Components:
Medically reviewed by Militian Inessa Mesropovna, PharmD. Last updated on 19.05.2022
Attention! Information on this page is intended only for medical professionals! Information is collected in open sources and may contain significant errors! Be careful and double-check all the information on this page!
For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested.
Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus.
As a sedative when used as premedication and following general anesthesia, Abacus may potentiate meperidine (Demerol®) and barbiturates, so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Abacus is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent.
The effectiveness of Abacus as an antianxiety agent for long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient.
Abacus injection is used to used to help control anxiety and tension caused by dental, nervous, and emotional conditions. It can also be used to help control anxiety and produce sleep before and after surgery. Abacus is also used to relieve symptoms of an allergic reaction (eg, hives, itching skin) caused by asthma and chronic urticaria.
Abacus is an antihistamine. It works by preventing the effects of a substance called histamine, which is produced by the body. Abacus is also used to control anxiety withdrawal symptoms in alcoholic patients. It is also used to control nausea and vomiting symptoms, and relieve anxiety in patients with certain heart disease.
Abacus is to be given by or under the supervision of your doctor.
For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested: in adults, 50-100 mg q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50-100 mg daily in divided doses.
For use in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus: in adults, 25 mg t.i.d. or q.i.d.; children under 6 years, 50 mg daily in divided doses; and over 6 years, 50-100 mg daily in divided doses.
As a sedative when used as a premedication and following general anesthesia: 50-100 mg in adults, and 0.6 mg/kg in children.
When treatment is initiated by the intramuscular route of administration, subsequent doses may be administered orally.
As with all medications, the dosage should be adjusted according to the patient's response to therapy.
How supplied
Abacus® Capsules (Abacus pamoate equivalent to Abacus)
25 mg: 100's (NDC 0069-5410-66), two-tone green capsules
50 mg: 100's (NDC 0069-5420-66), green and white capsules
Abacus®
Oral Suspension (Abacus pamoate equivalent to 25 mg Abacus per teaspoonful-5 mL): 1 pint (473 mL) bottles (NDC 0069-5440-93) and 4 ounce (120 mL) bottles (NDC 0069-5440-97) in packages of 4.
Shake vigorously until product is completely resuspended.
BIBLIOGRAPHY - Available on request.
Distributed by: Pfizer Labs Division of Pfizer Inc, NY, NY 10017. Revised: Nov 2016
See also:
What is the most important information I should know about Abacus?
Hypersensitivity to Abacus or any of the excipients of Abacus, to cetirizine, to other piperazine derivatives, to aminophylline, or to ethylenediamine; porphyria; acquired or congenital QT interval prolongation, risk factor to QT interval prolongation including known cardiovascular disease, significant electrolyte imbalance (hypokalemia and hypomagnesemia), family history of sudden cardiac death, significant bradycardia, concomitant use with drugs known to prolong the QT interval and/or induce Torsades de pointes.
Use in pregnancy: Abacus is contraindicated during pregnancy.
Animal studies have shown reproductive toxicity.
Abacus crosses the placental barrier leading to higher foetal than maternal concentrations.
To date, no relevant epidemiological data are available relating to exposure to Abacus during pregnancy.
In neonates whose mothers received Abacus during late pregnancy and/or labour, the following events were observed immediately or only a few hours after birth: Hypotonia, movement disorders including extrapyramidal disorders, clonic movements, CNS depression, neonatal hypoxic conditions or urinary retention.
Use in lactation: Abacus is contraindicated during lactation. Breastfeeding should be stopped if Abacus therapy is needed.
Cetirizine, the principal metabolite of Abacus, is excreted in human milk.
Although no formal studies have been performed on the excretion of Abacus in human milk, severe adverse effects have been shown in breastfed newborns/infants of Abacus treated mothers.
Use Abacus as directed by your doctor. Check the label on the medicine for exact dosing instructions.
- Abacus is usually given as an injection at your doctor's office, hospital, or clinic. If you will be using Abacus at home, a health care provider will teach you how to use it. Be sure you understand how to use Abacus. Follow the procedures you are taught when you use a dose. Contact your health care provider if you have any questions.
- Do not use Abacus if it contains particles, is cloudy or discolored, or if the vial is cracked or damaged.
- Keep this product, as well as syringes and needles, out of the reach of children and pets. Do not reuse needles, syringes, or other materials. Ask your health care provider how to dispose of these materials after use. Follow all local rules for disposal.
- If you miss a dose of Abacus and you are using it regularly, take it as soon as possible. If it is almost time for you next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.
Ask your health care provider any questions you may have about how to use Abacus.
There are specific as well as general uses of a drug or medicine. A medicine can be used to prevent a disease, treat a disease over a period or cure a disease. It can also be used to treat the particular symptom of the disease. The drug use depends on the form the patient takes it. It may be more useful in injection form or sometimes in tablet form. The drug can be used for a single troubling symptom or a life-threatening condition. While some medications can be stopped after few days, some drugs need to be continued for prolonged period to get the benefit from it.Abacus is used for the short-term treatment of nervousness and tension that may occur with certain mental/mood disorders (e.g., anxiety, dementia). It is also used to help manage withdrawal symptoms (e.g., anxiety, agitation) in alcoholics. Other uses include helping to decrease anxiety and nausea before/after surgery or during childbirth or helping certain narcotic pain relievers (e.g., meperidine) work better.
Abacus belongs to a class of medications called antihistamines. It is thought to work by affecting certain natural substances (acetylcholine, serotonin) in your body or by acting directly on certain parts of the brain. Abacus also blocks a natural substance that your body makes during an allergic reaction (histamine).
How to use Abacus intramuscular
This medication is given by injection into a muscle as directed by your doctor. Dosage is based on your age, weight, medical condition, and response to treatment.
If you are giving this medication to yourself at home, learn all preparation and usage instructions from your health care professional. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard medical supplies safely.
See also:
What other drugs will affect Abacus?
Central Nervous System Depressants: Patients should be informed that Abacus may potentiate the effects of barbiturates, other CNS depressants or drugs having anticholinergic properties.
Alcohol: Alcohol also potentiates the effects of Abacus.
Betahistine and Anticholinesterase Drugs: Abacus antagonizes the effects of betahistine and anticholinesterase drugs.
Tests Results: The treatment should be stopped at least 5 days before allergy testing or methacholine bronchial challenge, to avoid effects on the test results.
Monoamine Oxidase Inhibitors: Simultaneous administration of Abacus with MAOIs should be avoided.
Epinephrine: Abacus counteracts the epinephrine pressor action.
Phenytoin: In rats, Abacus antagonized the anticonvulsant action of phenytoin.
Cimetidine: Cimetidine 600 mg twice daily has been shown to increase the serum concentrations of Abacus by 36% and to decrease peak concentrations of the metabolite cetirizine by 20%.
CYP2D6 Substrates: Abacus is an inhibitor of cytochrome P-450 2D6 (Ki: 3.9 micrometer; 1.7 mcg/mL) and may cause at high doses drug-drug interactions with CYP2D6 substrates.
Effect on Other Drug Metabolism: Abacus has no inhibitory effect at 100 micrometer on UDP-glucuronyl transferase isoforms 1A1 and 1A6 in human liver microsomes. It inhibits cytochrome P-450 2C9/C10, 2C19 and 3A4 isoforms at concentrations (IC50: 19-140 micrometer; 7-52 mcg/mL) well above peak plasma concentrations. The metabolite cetirizine at 100 micrometer has no inhibitory effect on human liver cytochrome P-450 (1A2, 2A6, 2C9/C10, 2C19, 2D6, 2E1 and 3A4) and UDP-glucuronyl transferase isoforms. Therefore, Abacus is unlikely to impair the metabolism of drugs which are substrates for these enzymes.
Potent Inhibitors of Liver Enzymes: As Abacus is metabolized in the liver, an increase in Abacus blood concentrations may be expected when Abacus is co-administered with other drugs known to be potent inhibitors of liver enzymes.
Potentially Arrhythmogenic Drugs: Co-administration of Abacus with a potentially arrhythmogenic drug may increase the risk of QT prolongation and Torsades de pointes.
See also:
What are the possible side effects of Abacus?
Adverse effects are mainly related to CNS depressant or paradoxical CNS stimulation effects, to anticholinergic activity, or to hypersensitivity reactions.
Adverse reactions are ranked under headings of frequency using the following convention: Very common ≥1/10, common ≥1/100 to <1/10, uncommon ≥1/1,000 to <1/100, rare ≥1/10,000 to <1/1,000, very rare <1/10,000, not known (cannot be estimated from the available data).
Clinical Trial Data: The following adverse effects were reported in placebo-controlled clinical trials for Abacus and including 735 subjects exposed to Abacus up to 50 mg daily.
Nervous System Disorders: Very Common: Somnolence. Common: Headache. Uncommon: Dizziness, insomnia, attention disturbance.
Gastrointestinal Disorders: Common: Dry mouth. Uncommon: Constipation, nausea.
General Disorders and Administration Site Conditions: Common: Fatigue. Uncommon: Asthenia.
Post-Marketing Data: Immune System Disorders: Not Known: Hypersensitivity, anaphylactic shock.
Psychiatric Disorders: Not Known: Agitation, confusion, disorientation, hallucination.
Nervous System Disorders: Not Known: Sedation, tremor, convulsions, dyskinesia.
Eye Disorders: Not Known: Accommodation disorder, blurred vision.
Cardiac Disorders: Not Known: Tachycardia, prolonged electrocardiogram QT, Torsades de pointes.
Vascular Disorders: Not Known: Hypotension.
Respiratory, Thoracic and Mediastinal Disorders: Not Known: Bronchospasm.
Gastrointestinal Disorders: Not Known: Vomiting.
Hepatobiliary Disorders: Not Known: Abnormal liver function tests.
Skin and Subcutaneous Tissue Disorders: Not Known: Pruritus, erythematous rash, maculopapular rash, urticaria, dermatitis, angioneurotic edema, hyperhidrosis, fixed drug eruption, acute generalized exanthematous pustulosis, erythema multiforme, Stevens-Johnson syndrome.
Renal and Urinary Disorders: Not Known: Urinary retention.
General Disorders and Administration Site Conditions: Not Known: Malaise, pyrexia.
The following adverse reactions have been observed with cetirizine, the principal metabolite of Abacus: Thrombocytopenia, aggression, depression, tic, dystonia, paresthesia, oculogyric crisis, diarrhea, dysuria, enuresis, asthenia, edema, increased weight and could potentially occur with Abacus.
Each Abacus tablet contains Hydroxyzine diHCl 10 mg or 25 mg.
Each mL of Abacus syrup contains hydrozyxine diHCl 2 mg.
New Drugs/Drug News
Drug Repositioning and Pharmacophore Identification in the Discovery of Hookworm MIF Inhibitors
A rare case of eosinophilic cystitis involving the inside and outside of the urinary bladder associated with an infected urachal cyst
A case of reactivation of varicella–zoster virus after BNT162b2 vaccine second dose?
P2X7 Receptor Blockade Protects Against Acrolein-Induced Bladder Damage: A Potential New Therapeutic Approach for the Treatment of Bladder Inflammatory Diseases
Dynamic sleep MRI in obstructive sleep apnea: a systematic review and meta-analysis
The neurophysiological basis of bruxism
Impact de la pandémie COVID-19 sur le sommeil du personnel soignant
First-line treatment posterior tibial nerve stimulation in patients with interstitial cystitis/bladder pain syndrome
Efficacy and Safety of Drug Combinations for Chronic Pelvic Pain: Protocol for a Systematic Review
Using Prazosin to Treat Posttraumatic Stress Disorder and Associations: A Systematic Review
Safety and efficacy of pentosan polysulfate in patients with bladder pain syndrome/interstitial cystitis: a multicenter, double–blind, placebo–controlled, randomized study
Update on Nystagmus and Other Ocular Oscillations
Self-produced audio-visual animation introduction alleviates preoperative anxiety in pediatric strabismus surgery: a randomized controlled study
Impact of holding home stimulant(s) on agitation in a child and adolescent inpatient psychiatric population
Esophageal pressure monitoring for airway management during catheter ablation of atrial fibrillation
Higher prescription of antidepressants and/or anxiolytics amongchronic obstructive pulmonary disease patients
Dexamethasone use and mortality in hospitalized patients with coronavirus disease 2019: A multicentre retrospective observational study
Care of the Patient Using Cannabis
Clinicopathological Conference: 54-year-old with Facial Swelling for One Month